Helix Biopharma Corp.
HBP.TO
TSX
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 45.71% | 56.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.18% | -22.12% | |||
| Operating Income | -20.18% | 22.12% | |||
| Income Before Tax | -12.27% | 1.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.27% | 1.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.27% | 1.11% | |||
| EBIT | -20.18% | 22.12% | |||
| EBITDA | -20.13% | 22.04% | |||
| EPS Basic | -6.22% | 3.50% | |||
| Normalized Basic EPS | -4.92% | 2.40% | |||
| EPS Diluted | 49.26% | -102.00% | |||
| Normalized Diluted EPS | -4.92% | 2.40% | |||
| Average Basic Shares Outstanding | 5.93% | 2.13% | |||
| Average Diluted Shares Outstanding | 5.93% | 2.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||